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ABSTRACT
Objective To retrospectively evaluate the 12-month
effectiveness of the Endeavor zotarolimus-eluting stent
(ZES) in diabetic versus non-diabetic patients enrolled in
the E-Five Registry.
Design and Setting The E-Five Registry is
a prospective, multicentre registry of 8314 patients
presenting with symptomatic coronary artery disease
treated with the Endeavor (ZES). Patients were treated
at 188 centres located in 37 countries across Europe,
Latin America and Asia Paciﬁc.
Patients There were 2721 (32.7%) patients with
diabetes (DM) and among these patients 682 were
insulin-treated (ITDM) and 2039 were non-insulin-treated
diabetic patients (NITDM).
Interventions All enrolled patients received an Endeavor
ZES and were followed for 12 months.
Main outcome measurements The primary outcome
measure was major adverse cardiac event (MACE) at
12 months. Secondary endpoints included target lesion
revascularisation (TLR), target vessel revascularisation
(TVR), target vessel failure (TVF) and stent thrombosis.
Results Compared with non-DM patients, DM patients
had higher rates of MACE (9.7% vs 6.4%, p<0.001), TLR
(5.3% vs 4.0%, p¼0.028) and Academic Research
Consortium (ARC) deﬁnite and probable stent thrombosis
(1.5% vs 0.9%, p¼0.041). Compared with non-DM
patients, ITDM patients had higher rates of MACE
(12.6% vs 6.4%, p<0.001). ITDM patients had higher
rates of death (6.7% vs 1.7%, p<0.001), cardiac death
(4.5% vs 1.2%, p<0.001) and TLR (6.5% vs 4.0%,
p¼0.011) than non-DM patients.
Conclusions The Endeavor ZES performed well in DM
patients; however, DM patients experienced higher rates
of adverse clinical events compared with non-DM
patients.
Trial Reg No Clinical trial registration information: http://
www.clinicaltrials.gov; Unique identiﬁer: NTC00623441
INTRODUCTION
Patients with diabetes mellitus (DM) are at
increased risk of restenosis and other adverse
cardiac events following percutaneous coronary
intervention (PCI) with stent implantation when
compared with non-diabetic (non-DM) subjects.
Drug-eluting stents, when used in randomised
controlled trials, have improved the outcomes of
PCI with stent implantation.
1 That insulin therapy
is associated with adverse outcomes in patients
with coronary artery disease treated with PCI
remains controversial. Randomised controlled trials
have not included sufﬁcient numbers of patients to
fully answer this question. Registry data have
suggested that patients with insulin-treated dia-
betes mellitus (ITDM) have worse outcomes than
non-insulin treated (NITDM) diabetic patients.
2
The Endeavor zotarolimus-eluting stent (ZES)
(Medtronic CardioVascular, Santa Rosa, California,
USA) is a relatively recent addition to the drug-
eluting stent armamentarium and has been shown
to be effective for the treatment of single, de novo
coronary lesions in randomised, controlled trials
that included DM patients.
3e5 However, the
Endeavor ZES’s performance in DM patients in
a ‘real-world’ population with coronary artery
disease remains largely unknown.
In order to evaluate the effectiveness of the
Endeavor ZES in DM patients in a ‘real-world’
setting, we analysed the clinical outcomes of ITDM
and NITDM patients enrolled in the E-Five
Registry.
6 The E-Five Registry was a prospective,
non-randomised, multicentre, global registry in
which more than 8000 adult patients with coro-
nary artery disease who underwent single-vessel or
multi-vessel Endeavor ZES implantation were
enrolled without any speciﬁc anatomical or clinical
exclusion criteria. Twelve-month clinical safety and
performance outcomes for the E-Five Registry
patients were recently reported.
7 Here we report
the results of the E-Five diabetic subgroup analysis,
which compared the 12-month clinical outcomes
between non-DM and DM patients, and NITDM
and ITDM patients.
METHODS
Study design, population and objectives
The design and management of the E-Five Registry
has been described in detail elsewhere.
6 Brieﬂy, the
registry enrolled 8314 adult patients with coronary
artery stenosis who underwent single-vessel or
multivessel PCI with the Endeavor ZES at one of
188 hospitals in 37 countries including 24 in
Europe, three in South America, eight in Asia and
Australia, New Zealand, Mexico and India. There
were no speciﬁc anatomical or clinical exclusion
criteria, and the presence of multiple coronary
artery stenoses in multiple vessels did not preclude
the enrolment of patients in the registry. The
population of the E-Five Registry was thus
intended to include acute presentations and
complex patient and lesion subgroups.
For the E-Five diabetes subgroup study, 12-
month event data were compared retrospectively
between non-DM and DM patients and between
< An appendix is published
online only. To view these ﬁles
please visit the journal online
(http://heart.bmj.com).
1Barts and The London National
Health Service Trust, London,
UK
2Heart Institute,
Hadassah-Hebrew University
Medical Centre, Jerusalem,
Israel
3MonashHeart Monash Medical
Centre, Monash University,
Melbourne, Australia
4Instituto Dante Pazzanese de
Cardiologia, Sa ˜o Paulo, Brazil
5National Heart Institute, Kuala
Lumpur, Malaysia
6SGPGI Lucknow, Lucknow,
India
7A complete list of the E-Five
Investigators is provided in the
appendix
Correspondence to
Professor Martin T Rothman,
Department of Cardiology,
London Chest Hospital, London
E2 9JX, UK;
rothcons@dircon.co.uk
Accepted 25 January 2010
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
heart.bmj.com/site/about/
unlocked.xhtml
848 Heart 2010;96:848e853. doi:10.1136/hrt.2009.184150
Interventional cardiologyNITDM and ITDM patients. DM was the accepted diagnosis if
the patient presented with a prior diagnosis and was taking
diabetic-speciﬁc therapy; no speciﬁc laboratory conﬁrmatory
test was required. The adjudicated event data included major
adverse cardiac events (MACE), target lesion revascularisation
(TLR), target vessel revascularisation (TVR), target vessel failure
(TVF) and stent thrombosis. MACE was deﬁned as the
composite endpoint of death, myocardial infarction (MI; Q
wave and non-Q wave), emergency cardiac bypass surgery or
TLR. Non-Q wave MI was deﬁned as an elevated creatine kinase
(CK) of at least twice the upper limit of normal with the pres-
ence of elevated creatine kinase MB isoenzyme (CK-MB) and in
the absence of new pathological Q waves. TLR was deﬁned as
any percutaneous intervention or bypass surgery performed on
the index target lesion at any time after the index procedure.
TVR was deﬁned as any percutaneous intervention or bypass
surgery performed on the index target vessel at any time after
the index procedure. TVF was deﬁned as TVR, cardiac death or
MI. Stent thrombosis was deﬁned as a thrombotic occlusion or
stenosis of the stented target lesion, or in the absence of
angiogram, an ST-segment elevation MI in the territory of the
index vessel. In addition to the protocol deﬁnition, the Academic
Research Consortium (ARC) deﬁnitions of stent thrombosis
were applied to the dataset retrospectively, then analysed and
reported.
8 There was no mandatory angiographic follow-up in
the E-Five Registry protocol.
The E-Five Registry was conducted according to the Decla-
ration of Helsinki, and local ethics committees approved the
study protocol. Written, informed consent was obtained from
every patient. The authors had full access to data and take full
responsibility for the integrity of the data. All authors have read
and agree to the manuscript as written.
Data collection and management
The registry’s clinical data were prospectively collected by
dedicated research nurses on a web-based case report form, and
for 10% of the patients, the data were veriﬁed by study monitors
at hospital visits. Patient follow-up data were obtained during
Table 1 Baseline patient and lesion characteristics for all 8314 patients enrolled in the E-Five Registry stratiﬁed by diabetes status
Characteristic
Non-DM DM
p Value
NITDM ITDM
p Value
(n[5593) (n[2721) (n[2039) (n[682)
(n[6884 lesions) (n[3455 lesions) (n[2595 lesions) (n[857 lesions)
Age
(years) mean6SD
62.31611.34
(5593/5593)
65.32610.16
(2721/2721)
<0.001 64.90610.23
(2039/2039)
66.5769.85
(682/682)
<0.001
Female (%) 19.8
(1106/5593)
30.7
(834/2721)
<0.001 28.2
(576/2039)
37.8
(258/682)
<0.001
Unstable angina (%) 33.1
(1851/5593)
35.6
(969/2721)
0.023 35.6
(725/2039)
35.8
(244/682)
0.926
Prior MI (%) 31.8
(1776/5593)
33.0
(897/2721)
0.271 32.0
(653/2039)
35.8
(244/682)
0.074
AMI #72 hours* (%) 14.8
(829/5593)
11.9
(324/2721)
<0.001 12.1
(247/2039)
11.3
(77/682)
0.586
AMI <6 hours*y (%) 5.2
(145/2810)
3.1
(39/1263)
0.003 2.8
(27/954)
3.9
(12/309)
0.347
AMI 6e24 hours*y (%) 5.3
(149/2810)
4.4
(56/1263)
0.278 4.1
(39/954)
5.5
(17/309)
0.339
Prior PCI (%) 25.5
(1426/5593)
25.0
(680/2721)
0.629 23.5
(480/2039)
29.3
(200/682)
0.003
Prior CABG (%) 7.3
(407/5593)
8.1
(220/2721)
0.199 7.2
(147/2039)
10.7
(73/682)
0.005
Current smoker (%) 25.4
(1419/5593)
17.0
(463/2721)
<0.001 18.0
(368/2039)
13.9
(95/682)
0.013
Hypertension (%) 63.7
(3564/5593)
78.6
(2140/2721)
<0.001 77.5
(1580/2039)
82.1
(560/682)
0.011
Treated hyperlipidaemia (now or in past)
(%)
60.8
(3400/5593)
67.7
(1843/2721)
<0.001 67.7%
(1380/2039)
67.9%
(463/682)
0.962
Moderate renal impairment (creatinine
140e220 mol/l)*y (%)
3.6
(164/4540)
7.0
(153/2180)
<0.001 5.5
(91/1643)
11.5
(62/537)
<0.001
Severe renal impairment (creatinine
>220 mol/l)*y (%)
1.0
(47/4540)
3.3
(73/2180)
<0.001 2.3
(38/1643)
6.5
(35/537)
<0.001
B2/C lesions (%) 60.0
(4128/6884)
60.8
(2101/3455)
0.418 61.0
(1585/2598)
60.2
(516/857)
0.678
Lesion length (mm) 18.49610.54
(6881)
18.55610.74
(3451)
0.790 18.57610.84
(2595)
18.49610.46
(857)
0.849
Number of stents implanted 1.1960.48
(6884)
1.1860.47
(3455)
0.242 1.1760.46
(2598)
1.1960.50
(857)
0.340
Total stent length (mm) 23.49612.21
(6884)
23.45612.21
(3455)
0.902 23.51612.41
(2598)
23.29611.60
(857)
0.645
Number of lesions treated, mean6SD 1.2360.51 (5593/5593) 1.2760.56
(2721/2721)
0.002 1.2760.57
(2039/2039)
1.2660.51
(682/682)
0.452
Reference vessel diameter (mm)
mean6SD
2.9560.47
(6884)
2.9060.46
(3455)
<0.001 NA NA e
*The time frame provided reﬂects the number of hours from the onset of AMI symptoms to the time of percutaneous coronary intervention.
yHalfway through the E-Five Registry’s enrolment, the case report form was modiﬁed to gather further detail about patients’ baseline clinical characteristics, including renal function and the
time between the onset of AMI symptoms and percutaneous coronary intervention. Thus, the denominator reﬂects the total number of patients in which the modiﬁed case report form was used.
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; DM, diabetes mellitus; ITDM, insulin-treated diabetes mellitus; MI, myocardial infarction; NITDM, non-insulin-treated
diabetes mellitus; PCI, percutaneous coronary intervention.
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Interventional cardiologya scheduled clinic visit whenever possible or alternatively by
phone contact. All events related to endpoints were reported to
an independent clinical endpoints committee, which consisted
of cardiologists not taking part in the study.
Device description
The Endeavor ZES used to treat patients in the E-Five Registry is
composed of three different components: (1) the low-proﬁle,
thin-strut, cobalt-alloy Driver stent (Medtronic CardioVascular,
Santa Rosa, California, USA); (2) a proprietary biomimetic
phosphorylcholine polymer; and (3) zotarolimus, an anti-
proliferative drug that is a synthetic analogue of sirolimus and
has a similar mechanism of action. The Endeavor ZES carries
a dose concentration of 10 mg zotarolimus/mm stent length.
Experimental evaluation of the elution proﬁle of zotarolimus has
revealed that approximately 95% of the active drug is eluted
from the stent within 15 days of implantation.
9 For the E-Five
Registry, the Endeavor ZES was available in diameters of
2.25e4.0 mm and in lengths of 8e30 mm.
Statistical methods
The primary analytical population consisted of all enrolled
patients in whom an Endeavor stent was attempted and/or
implanted. The clinical outcomes of DM patient (ITDM and
NITDM) and non-DM patient subgroups were evaluated.
The baseline demographic and lesion characteristics, proce-
dural characteristics, and the clinical outcomes were assessed
and presented here based on the presence and the nature of
treatment of DM. Categorical variables were reported using
percentages and counts, and continuous variables by the means
and standard deviations. The times to MACE and stent
thrombosis were summarised and displayed using cumulative
incidence curves by Kaplan-Meier methods. Subgroups were
compared for baseline characteristics and clinical outcomes. p
Values were calculated using a two-sample t test for continuous
variables or Fisher’s exact test for categorical variables. In addi-
tion, clinical outcomes were compared between subgroups using
adjusted p values, calculated using logistic regression adjusted
for propensity scores. Propensity scores were calculated using
the following baseline variables: age, sex, prior MI, prior percu-
taneous transluminal coronary angioplasty, prior coronary artery
bypass graft surgery, acute MI (<72 hours), hypertension,
hypercholesterolaemia, smoking, left anterior descending coro-
nary artery (LAD) (vs non-LAD), B2C (vs AB1), lesion length
($27 mm vs <27 mm) and reference vessel diameter (>3.5 mm
vs #3.5 mm).
RESULTS
Patient characteristics
Baseline demographic, clinical and procedural characteristics of
all 8314 registry patients are listed in table 1. Of the 2721
(32.7%) registry patients with diabetes, 682 (25.1%) had ITDM.
Overall, DM patients compared with non-DM patients tended
to be older, female and non-smokers with a higher incidence of
hypertension, hyperlipidaemia, unstable angina and moder-
ateeto-severe renal impairment. At the time of the baseline
procedure, the number of lesions treated was higher in DM
patients than in non-DM patients.
Compared with NITDM patients, ITDM patients tended to
be older, female and more frequently non-smokers. ITDM
patients also had a higher incidence of hypertension and
moderateeto-severe renal impairment than NITDM patients
and were more likely to have undergone previous coronary
revascularisation.
Clinical outcomes
Of the 8314 registry patients, 12-month follow-up data were
available for 7832 (94.2%).
Major adverse cardiac events
DM patients experienced a higher MACE rate than non-DM
patients (table 2). Of the MACE components, DM patients had
higher rates of death and, in particular, cardiac-related death and
TLR than non-DM patients. The rate of MI between DM and
non-DM patients was not signiﬁcantly different, however.
ITDM patients, compared with NITDM patients, had
a higher rate of MACE (table 3). Of the MACE components,
ITDM patients had higher rates of death and cardiac death than
NITDM patients. MI and TLR rates were not signiﬁcantly
different between the two groups.
The cumulative incidence of MACE events for the non-DM,
NITDM and ITDM patient groups is shown in ﬁgure 1A, and
the cumulative incidence of TLR for the three patient groups is
shown in ﬁgure 1B.
DM patients, compared with non-DM patients, experienced
a higher rate of TVR (table 2). TVR was not signiﬁcantly
different between the ITDM and NITDM groups (table 3). DM
patients, compared with non-DM patients, also experienced
Table 2 Comparison of 12-month clinical outcomes between diabetic
and non-diabetic patients enrolled in the E-Five Registry
Outcome
Non-DM DM
(n[5269) (n[2563) p Value
% (n) % (n) (adjusted*)
MACE 6.4 (339) 9.7 (248) <0.001
Death-all 1.7 (87) 4.1 (104) <0.001
Cardiac-related death 1.2 (65) 2.7 (70) <0.001
MI 1.5 (81) 1.8 (47) 0.531
Q wave 0.4 (19) 0.5 (12) 0.282
Non-Q wave 1.2 (63) 1.4 (35) 0.928
Emergent CABG 0.0 (0) 0.0 (0) NA
TLR 4.0 (213) 5.3 (136) 0.028
CABG 0.6 (31) 0.7 (19) 0.322
PTCA 3.5 (187) 4.8 (124) 0.023
TVR 4.6 (240) 5.7 (147) 0.053
TVRdnot target lesion 0.7 (37) 0.6 (15) 0.415
TVF 6.5 (341) 8.7 (224) 0.002
ARC deﬁnite stent
thrombosis
0.5 (27) 0.9 (22) 0.092
0e30 days 0.3 (14) 0.5 (14) 0.067
31e365 days 0.3 (14) 0.4 (9) 0.547
ARC deﬁnite and probable
stent thrombosis
0.9 (49) 1.5 (39) 0.041
0e30 days 0.6 (30) 1.1 (29) 0.015
31e365 days 0.4 (20) 0.4 (11) 0.823
All ARC stent thrombosis 1.4 (73) 2.8 (71) <0.001
0e30 days 0.6 (30) 1.1 (29) 0.015
31e365 days 0.9 (45) 1.7 (44) 0.007
Per protocol stent thrombosis 0.8 (41) 1.6 (41) 0.002
0e30 days 0.6 (29) 1.3 (33) 0.001
31e365 days 0.2 (13) 0.3 (8) 0.577
ARC, Academic Research Consortium; CABG, coronary artery bypass grafting; MACE,
major adverse cardiac events; MI, myocardial infarction; NA, not applicable; PTCA,
percutaneous transluminal coronary angioplasty; TLR, target lesion revascularisation; TVF,
target vessel failure; TVR, target vessel revascularisation.
*p Values were calculated using logistic regression adjusted for propensity scores.
Propensity scores were calculated using the following baseline variables: age, sex, prior MI,
prior percutaneous transluminal coronary angioplasty, prior coronary artery bypass graft
surgery, acute MI (<72 h), hypertension, hypercholesterolemia, smoking, left anterior
descending coronary artery (LAD) (vs non-LAD), B2C (vs AB1), lesion length ($27 mm vs
<27 mm), and reference vessel diameter (>3.5 mm vs #3.5 mm).
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Interventional cardiologya higher rate of TVF (table 2). The rate of TVF was higher in
ITDM patients compared with NITDM patients. (table 3).
Stent thrombosis
DM patients, compared with non-DM patients, had higher rates
of ARC deﬁnite and probable stent thrombosis (table 2). There
was no statistically signiﬁcant difference in ARC deﬁnite and
probable stent thrombosis between the ITDM and NITDM
groups (table 3). Most ARC deﬁnite and probable stent throm-
bosis events occurred early, before 30 days post ZES implanta-
tion and there were no differences in late ARC deﬁnite and
probable stent thrombosis among any of the study groups. The
cumulative incidence of stent thrombosis in non-DM, NITDM
and ITDM patient groups is shown in ﬁgure 1C.
Antiplatelet therapy
Most DM and non-DM patients received dual antiplatelet
therapy (DAPT, aspirin and clopidogrel or ticlopidine) at 30 days
(97.6% and 98.1%, p¼0.152). The proportions of patients
continuing on DAPT declined over time across all groups
although by 12 months, patients with DM were more likely
than non-DM patients to be receiving DAPT (63.4% vs 60.5%,
p¼0.016). Patients with ITDM and NITDM were equally likely
to receive DAPTat 12 months (63.5% vs 63.3%, p¼0.961).
DISCUSSION
In this study of ‘real-world’ patients who underwent ZES stent
implantation, DM patients, compared with non-DM patients,
were found to have signiﬁcantly higher rates of MACE, cardiac
death, TLR and TVR. ARC deﬁnite and probable stent throm-
bosis was signiﬁcantly more common in DM patients than non-
DM patients. These ﬁndings are consistent with previously
published registry analyses.
10 11
The current study presents the largest analysis of patients in
which the outcomes of NITDM compared with ITDM patients
implanted with a drug-eluting stent have been studied. The high
rate of follow-up at 94.2% is consistent with follow-up rates of
other drug-eluting stent registries (88%e95%) and combined
with the independent adjudication of all endpoint events and
a further 10% random monitoring, leads to a high degree of
conﬁdence in these data.
11e13 In this study, ITDM patients were
found to have signiﬁcantly greater rates of MACE, all-cause
death and cardiac death than NITDM patients, as well as
a signiﬁcantly greater rate of TVF. These results show that
although the presence of ITDM did not confer an increased risk
of ARC deﬁnite or probable stent thrombosis compared with
NITDM, the subgroup of diabetic patients treated with insulin
was at a statistically higher risk of stent thrombosis than non-
DM patients during the ﬁrst 30 days after the procedure. Most
patients, regardless of their diabetes status, received DAPT
during this period although DM patients were more likely to
continue DAPT for 12 months than non-DM patients. It is
unclear what part continued DAPT played in the risk for late
stent thrombosis among DM patients.
The association of insulin treatment with increased rates of
both all-cause mortality and cardiac death in this registry may
have several explanations. Insulin therapy is generally reserved
for patients in whom tablet treatment of DM has failed. This
suggests that the patients may have had less well controlled
DM, for longer duration, at the time of enrolment in the study.
The increased co-morbidity associated with longstanding DM
may have contributed to the excess rates of all-cause mortality
seen in the ITDM group. Most ITDM patients have greater
levels of insulin resistance than NITDM patients. Insulin
resistance is associated impaired vascular production of nitric
oxide, increased endothelin-1 and angiotensin-II and increased
vascular production of cytokines.
14 These processes work in
synergy with the production of pro-coagulant factors, leading to
accelerated atherogenesis and increased propensity to throm-
bosis. Furthermore, stent restenosis is known to be mediated by
cellular proliferation cascades inﬂuenced adversely by insulin.
There remains confusion as to whether the beneﬁts of improved
glycaemic control that are achievable with insulin therapy
outweigh the possible detrimental effects on the vascular
endothelium and its response to injury. Randomised trials have
compared outcomes of drug-eluting stent implantation in
ITDM and NITDM patients. The number of patients in these
subgroup studies has been small, and it is thus difﬁcult to draw
conclusions from the available data. In the Sirolimus-Eluting
Stent in De Novo Native Coronary Lesions (SIRIUS) substudy,
the outcome of drug-eluting stent in 131 patients was investi-
gated with follow-up angiography.
15 In this study patients with
ITDM (n¼38) had higher rates of MACE and TLR than those
patients with NITDM (n¼93) (p<0.001). In Taxus IV, the
1-year rate of MACE progressively increased from patients
without diabetes, to those managed with oral medications
(n¼213), to those requiring insulin (n¼105) (p<0.001).
1
Registry analyses of outcomes of drug-eluting stent implanta-
tion according to diabetes status have also been published,
although these have been in small numbers of patients. In 293
diabetic patients in the Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent
Evaluated at Rotterdam Cardiology Hospital (T-SEARCH)
Table 3 Comparison of 12-month clinical outcomes between
insulin-treated diabetics and non-insulin-treated diabetics enrolled
in the E-Five Registry
Outcome
ITDM NITDM
p Value
(adjusted*)
(n[644) (n[1919)
% (n) % (n)
MACE 12.6 (81) 8.7 (167) 0.019
Death-all 6.7 (43) 3.2 (61) <0.001
Cardiac death 4.5 (29) 2.1 (41) 0.004
MI 1.7 (11) 1.9 (36) 0.622
Q wave 0.2 (1) 0.6 (11) 0.299
Non-Q wave 1.6 (10) 1.3 (25) 0.959
Emergent CABG 0.0 (0) 0.0 (0) NA
TLR 6.5 (42) 4.9 (94) 0.221
CABG 0.5 (3) 0.8 (16) 0.408
PTCA 6.2 (40) 4.4 (84) 0.152
TVR 7.0 (45) 5.3 (102) 0.227
Not target lesion 0.5 (3) 0.6 (12) 0.601
TVF 11.0 (71) 8.0 (153) 0.050
ARC deﬁnite ST 1.2 (8) 0.7 (14) 0.305
0e30 days 0.8 (5) 0.5 (9) 0.370
31e365 days 0.6 (4) 0.3 (5) 0.295
ARC deﬁnite+ prob. ST 2.2 (14) 1.3 (25) 0.158
0e30 days 1.6 (10) 1.0 (19) 0.253
31e365 days 0.8 (5) 0.3 (6) 0.195
*p Values were calculated using logistic regression adjusted for propensity scores.
Propensity scores were calculated using the following baseline variables: age, sex, prior MI,
prior percutaneous transluminal coronary angioplasty, prior coronary artery bypass graft
surgery, acute MI (<72 h), hypertension, hypercholesterolemia, smoking, left anterior
descending coronary artery (LAD) (vs non-LAD), B2C (vs AB1), lesion length ($27 mm vs
<27 mm), and reference vessel diameter (>3.5 mm vs #3.5 mm).
ARC, Academic Research Consortium; CABG, coronary artery bypass grafting; DM,
diabetes mellitus; ITDM, insulin-treated diabetes mellitus; MACE, major adverse cardiac
events; MI, myocardial infarction; NA, not applicable; NITDM, non-insulin-treated diabetes
mellitus; PTCA, percutaneous transluminal coronary angioplasty; ST, stent thrombosis; TLR,
target lesion revascularisation; TVR, target vessel revascularisation; TVF, target vessel
failure.
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Interventional cardiologyregistries, insulin treatment was not found to be an independent
predictor of MACE.
16
The presence of DM is recognised as a predictor of stent
occlusion after bare metal stent implantation, and has been
shown to be an independent predictor of stent thrombosis in
drug-eluting stent implantation.
17 The increased incidence of
stent thrombosis in DM patients treated with either a pacli-
taxel-eluting or a sirolimus-eluting stent has recently been
conﬁrmed.
18 The impact of diabetes status upon the incidence of
drug-eluting stent thrombosis is unclear. The e-Cypher registry
examined the safety of the sirolimus-eluting stent in daily
clinical practice. In the e-Cypher registry, insulin treatment was
found to be to be an independent predictor of stent thrombosis
in DM patients.
11 An increased need for TLR in the DM popu-
lation was observed in the current study which may be related
to the greater complexity of the patients in the E-Five Registry
(eg, longer length lesions, small diameter vessels, etc).
7 Addi-
tionally, the relatively short time-course for follow-up of E-Five
Registry patients may favour ﬁnding in-stent restenosis rather
than new lesions or lesion progression that warrants further
intervention.
This study had several limitations. By design it was a registry
of unselected patients, and thus there was no randomisation. In
addition, the study was conﬁned to patients with a zotarolimus-
eluting stent. The non-randomised nature of the study
prevented any further analysis of the outcome differences
between ITDM and NITDM patients. It should also be noted
that the analysis of patients with and without DM enrolled in
the E-Five Registry was retrospective in nature.
In conclusion, this study conﬁrmed the safety and effective-
ness of the ZES in the treatment coronary artery disease in
patients with DM. However, there is clearly a difference in
outcomes depending on the treatment regimen, insulin or not.
Whether it is the impact of the antecedent duration of diabetes,
Figure 1 Kaplan-Meier curves showing cumulative incidence of (A) major adverse cardiac events (MACE) in non-diabetics (non-DM),
insulin-treated diabetics (ITDM) and non-insulin-treated diabetic (NITDM) patients; (B) target lesion revascularisation (TLR) in non-diabetics
(non-DM), insulin-treated diabetics (ITDM) and non-insulin-treated diabetic (NITDM) patients; (C) deﬁnite or probable stent thrombosis in non-diabetics
(non-DM), insulin-treated diabetics (ITDM), and non-insulin-treated diabetic (NITDM) patients.
Glossary of study names
RESEARCH
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology
Hospital
T-SEARCH
Taxus-Stent Evaluated at Rotterdam Cardiology Hospital
SIRIUS
Sirolimus-Eluting Stent in De Novo Native Coronary Lesions
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Interventional cardiologythe insulin therapy itself, the need for insulin therapy or other
factors, there is a clear disadvantage to having diabetes, but
whether any drug-eluting stent can offset these factors is
unclear. Further work is required to deﬁne treatment strategies
and drug-eluting stent type to bring diabetic outcomes into line
with those of non-diabetics.
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